Cheryl Guttman Krader
Urologists show low adherence to value-based care pathway
Urologists’ adherence to value-based care pathways for BPH surgery is extremely low and only modestly improved when given individualized feedback on patient outcomes, costs, and practice patterns relative to peers, say UCLA researchers.
Should RCC immunotherapy continue after progression?
Some patients being treated with nivolumab (Opdivo) for advanced renal cell carcinoma may still derive benefit if continued on the immunotherapy after disease progression, according to an analysis of phase III study data.
Urothelial Ca immunotherapy approved for first-line use
“Modern immunotherapy is active in advanced urothelial carcinoma and represents the most important advancement in the treatment of this disease in over 30 years,” says investigator Arjun V. Balar, MD.
Study: Consumer ads prompt men to seek TRT
Findings of an ecologic study indicate that direct-to-consumer advertising for testosterone therapy influenced men to seek treatment and was accompanied by increased testosterone prescribing, including initiation in men without clear indications for use.
5-ARIs linked to increased risk of self-harm, depression
Use of 5α-reductase inhibitors for the treatment of BPH appears to be associated with increased risks of self-harm and depression, according to a population-based, retrospective, matched cohort study of men in Canada.
Immunotherapy for GU Ca: A primer for urologists
This article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
What’s new in prostate Ca tests: Markers, imaging
In this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.
Biomarkers for bladder cancer: Current and future
The role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
Small molecule RNA inhibitor shows promise in PCa
Targeted treatment with a small molecule RNA inhibitor demonstrates promising activity for promoting apoptosis of prostate cancer cells in culture, report investigators from Scripps Florida.
Combination immunotherapy may raise response rate in mRCC
“The data from our study show that combination therapy [for metastatic renal cell carcinoma] may offer a much higher response rate with manageable side effects,” says study author Jianjun Gao, MD, PhD.

Poll